Celon Pharma (CLN.WA)

Executive Summary

Celon Pharma S.A. is a Polish biopharmaceutical company listed on the Warsaw Stock Exchange (CLN.WA) with an integrated business model combining proprietary R&D in small-molecule drugs and a generic drug manufacturing and distribution segment. The proprietary pipeline includes 11 candidates focused on oncology and CNS disorders, with key programs such as esketamine DPI for major depressive disorder and bipolar depression (Phase 2 completed), CPL500036 for schizophrenia and Parkinson's disease (Phase 2 completed), and CPL207280 for type 2 diabetes (Phase 2 unknown status). Revenue from generics funds the R&D pipeline. The company operates GMP/GLP-compliant facilities and has a market valuation of approximately $1.15B. Recent trial completions position Celon Pharma for potential regulatory milestones and partnership opportunities, though the pipeline is still early-stage and faces typical clinical development risks.

Upcoming Catalysts (preview)

• TBDEsketamine DPI regulatory filing or Phase 3 initiation for major depressive disorder60% success
• TBDCPL500036 Phase 2 results influencing Phase 3 design for schizophrenia or Parkinson's disease50% success
• TBDCPL207280 Phase 2 data readout for type 2 diabetes40% success